The invention relates to the use of viral vectors able to stably integrateinto the genome of thymic stromal cells, or of intrathymic lymphocytes orlymphocytes precursors, for the manufacture of a medicine intended forintrathymic administration in the frame of the prevention or treatment ofgenetic immunodeficiencies, acquired immunodeficiencies, or for the inductionof immune tolerance of the organism to self or non-self gene products, cellsor tissues, or for the prevention or treatment of autoimmune diseases.
